Kyprolis Wins Full Monotherapy OK, Broader Combo Use

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.